Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study
Titel:
Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study
Auteur:
von Pawel, J. Bordoni, R. Satouchi, M. Fehrenbacher, L. Cobo, M. Han, J.Y. Hida, T. Moro-Sibilot, D. Conkling, P. Gandara, D.R. Rittmeyer, A. Gandhi, M. Yu, W. Matheny, C. Patel, H. Sandler, A. Ballinger, M. Kowanetz, M. Park, K.